CRNX · Crinetics Pharmaceuticals, Inc.
$83.86
+0.01 (+0.01%)
At close · Jul 28
Market Cap
$8.84B
Shares
105.44M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$83.86
Open$83.87
Day$83.84–83.98
52W$25.83–84.00
Avg vol 30d6.3M
Short int6.2M · 5.9% float · 1.0d
Short vol11%
Last earningsAug 4, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
Next earnings call
Aug 4, 2026
Scheduled
· in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+85%
above
Price vs 50-day avg
+64%
above
RSI (14)
92
overbought
MACD trend
Negative
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+127%
trailing
6-month return
+68%
trailing
YTD return
+80%
this year
Relative strength
+60%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $51 › 200d $45 — 50d above 200d
Institutional flow
Accumulating
41 of 244 funds reported for Jun 30 · net +73.7K sh shares · +11 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.89% of float · ▼ -55.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
244 holders — near 3-yr high, broad support
Squeeze score
56
elevated · 0–100
Fundamentals
Revenue growth
−74%
Y/Y
EPS growth
−34%
Y/Y
Free cash flow
$-383.7M
Balance sheet
$101.5M
net cash
Quant / Vol
risk profile
Volatility
114%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
2.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
Non-GAAP operating expenses
· 2026
Non-GAAP
Initiated
$480M – $520M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+85%
Bullish
Price vs 50-day avg
+64%
Bullish
RSI (14)
92
Bearish
MACD trend
Negative
Bearish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $51 › 200d $45 — 50d above 200d
Institutional flow
Accumulating
41 of 244 funds reported for Jun 30 · net +73.7K sh shares · +11 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.89% of float · ▼ -55.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
244 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $26
Now $84 · 100%
52-wk high $84
vs 200-day avg +85%
vs 50-day avg +64%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| enrollment forms | 232 | first quarter of 2026 | — |
| percentage of patients treated with PALSONIFY on reimbursed therapy | 70% | end of the first quarter of 2026 | — |
| Net product revenue from the U.S. commercial launch of PALSONIFY | $5.4M | fourth quarter ended December 31, 2025 | — |
| Non-GAAP operating expenses non-GAAP | $428,475K | year ended December 31, 2025 | — |
| Cash, cash equivalents, and investments | $1.4B | as of January 8, 2026 | — |
| Enrollment forms received | 200 | fourth quarter of 2025 | — |
| Net product revenue from PALSONIFY | $5M | fourth quarter of 2025 | — |
| Unique PALSONIFY prescribers | 125 | fourth quarter of 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRNX
this stock
Crinetics Pharmaceuticals, Inc.
|
$8.84B | +80.2% | -74.1% | — | 5.9% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.3% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRNX | -0.1% | +127.0% | +67.9% | +124.1% | +80.2% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +0.9% | +127.0% | +60.4% | +124.9% | +71.5% |
Key facts
CIK
1658247
CUSIP
22663K107
13F (30d)
39 filings
39 filers
Visit website
Investor relations